Know Cancer

forgot password

A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)

Phase 3
18 Years
Not Enrolling
Renal Cell Carcinoma, Kidney Cancer

Thank you

Trial Information

A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)

A preoperative 124I-cG250 PET scan may distinguish between clear cell and non-clear cell
renal carcinoma in patients with renal masses. Studies of imaging characteristics of 124I by
a variety of PET cameras, quantification of tumor uptake of 124I-labeled antibody and
correlation with biopsy measurement of tumor and normal tissue have met with encouraging
results. As clear cell renal cancers are associated with an aggressive phenotype their a
priori determination may help guide appropriate surgical/therapeutic management.

Inclusion Criteria:

- Subject is over 18 years of age.

- Presence of a renal mass.

- Scheduled for surgical resection of renal mass (partial or total nephrectomy, open or
laparoscopic technique).

- Expected survival of at least 3 months.

- ECOG < 2.

- The following laboratory results should be within the following limits within the
last 2 weeks prior to study day 1:

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

- Platelet count ≥ 100 x 109/L

- Serum bilirubin ≤ 2.0 mg/dL

- Aspartate aminotransaminase (AST) ≤ 2.5 x ULN

- Alanine aminotransferase (ALT) ≤ 2.5 x ULN

- Serum creatinine ≤ 2.0 mg/dL (calculated creatinine clearance >45 ml/min)

- Negative serum pregnancy test; to be performed on female patients of childbearing
potential within 24 hours prior to receiving investigational product. All females of
childbearing potential must indicate intent to avoid pregnancy and must use an
accepted, effective method of contraception for the duration of the study.

- Recovered from toxicity of any prior therapy.

- Able and willing to give valid written informed consent.

Exclusion Criteria:

- Metastasis of primary tumor other than RCC.

- Prior history of malignancy within the last 5 years.

- Prior exposure to murine proteins or chimeric antibodies.

- Intercurrent medical condition that may limit the amount of antibody to be

- Intercurrent medical condition that renders the patient ineligible for surgery.

- New York Heart Association Class III/IV cardiac disease.

- History of autoimmune hepatitis.

- Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to 124I-cG250
infusion on day 1.

- Mental impairment that may compromise the ability to give informed consent and comply
with the requirements of the study.

- Lack of availability for immunological and clinical follow-up assessments.

- Participation in any other clinical trial involving another investigational product
within 4 weeks prior to enrolment.

- Women who are pregnant or breastfeeding.

- Allergy to iodine, hyperthyroidism, or Grave's Disease.

- Known allergic reaction to human serum albumin.

- Contraindication for contrast-enhanced CT or PET/CT.

- Contraindication to potassium iodide intake (see package insert).

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Binary qualitative reading of 124I-cG250 based PET/CT imaging in renal masses and adjacent normal organ tissues to decide on the presence or absence of ccRCC.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Chaitanya Divgi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Pennsylvania


United States: Food and Drug Administration

Study ID:




Start Date:

March 2008

Completion Date:

Related Keywords:

  • Renal Cell Carcinoma
  • Kidney Cancer
  • Renal Mass
  • Clear Cell Renal Cell Carcinoma
  • Cancer of Kidney
  • Kidney Cancer
  • Neoplasms
  • cG250
  • antibody, monoclonal
  • Iodine 124
  • Positron-Emission Tomography
  • Kidney
  • Renal Cancer
  • Renal Neoplasms
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms



University of Michigan Ann Arbor, Michigan  48109-0624
Cleveland Clinic Foundation Cleveland, Ohio  44195
Memorial Sloan-Kettering Cancer Center New York, New York  10021
Stanford University Medical Center Stanford, California  94305-5408
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Duke University Medical Center Durham, North Carolina  27710
Hospital of the University of Pennsylvania Philadelphia, Pennsylvania  19104
Ohio State University Columbus, Ohio  43210
Lahey Clinic Burlington, Massachusetts  01805
Nevada Cancer Institute Las Vegas, Nevada  89135
MD Anderson Houston, Texas  77230
David Geffen School of Medicine, UCLA Los Angeles, California  90095
H. Lee Moffitt Cancer Center & Research Center Tampa, Florida  33612
UNC School of Medicine-Chapel Hill Chapel Hill, North Carolina  27599